Aristotle
Aristotle Atlantic Partners Core Equity Strategy
Jun 2026 → Jun 2026
Our archive holds 1 letter from this strategy, behind 4 investment theses and positions in 9 companies. Every quote below is copied verbatim from the letter it came from.
1 letter in a year · follow all of Aristotle for every strategy.
Performance
as of Jun 30, 2026 · net of fees · USD · Core Equity Composite (net)
- YTD+9.6%index +10.2%
- 1Y+21.2%index +22.3%
- 3Y · /yr+20.9%index +20.6%
- 5Y · /yr+12.0%index +13.4%
- 10Y · /yr+15.6%index +15.5%
- Inception · /yr+14.4%index +14.3%
Index: S&P 500 Index
| YTD | 1Y | 3Yper year | 5Yper year | 10Yper year | Since inceptionper year | |
|---|---|---|---|---|---|---|
| Aristotle Atlantic Partners Core Equity Strategy | +9.6% | +21.2% | +20.9% | +12.0% | +15.6% | +14.4% |
| S&P 500 Index | +10.2% | +22.3% | +20.6% | +13.4% | +15.5% | +14.3% |
Calendar years
- 2025+18.8%index +17.9%
- 2024+26.6%index +25.0%
- 2023+23.3%index +26.3%
- 2022−21.9%index −18.1%
- 2021+24.6%index +28.7%
- 2020+26.3%index +18.4%
- 2019+35.3%index +31.5%
- 2018−5.4%index −4.4%
- 2017+21.9%index +21.8%
- 2016+10.0%index +12.0%
Since inception: Since Inception (8/1/2013)
Disclaimer
These figures are copied from the manager’s latest letter, as of Jun 30, 2026. They were extracted automatically, have not been verified by HF Best Ideas and may contain errors. They cover a single share class, in the currency and fee basis stated above; other share classes and your own returns will differ. This is not investment advice, nor an offer to buy or sell any fund. Past performance does not predict future returns.
Read full disclosures →What it bought and sold
Guardant Health contributed to performance in the second quarter following a string of positive developments, as several catalysts played out during the quarter.
We initiated Advanced Micro Devices, as the company's roadmap and rack-scale system capability now position it as a credible second source in data center central processing unit (CPU) and accelerated compute, a structural shift in markets that have historically operated as single-vendor franchises, with corresponding implications for pricing power and customer allocation.
We sold Synopsys and see its core electronic design automation (EDA) software business growth decelerating, with the business ex-Ansys growing only high single digits, and fiscal year 2026 remains a “transition year” that could slow into the low single digits.
We initiated Micron Technology on the view that the memory industry has entered a structurally longer and stronger upcycle than the historical two- to three-year pattern, with signs pointing to a four- to five-year duration.
We view Exxon Mobil as a compelling investment thesis built on its strong balance sheet, flexible capital program and advantaged growth portfolio.
We sold Boston Scientific on concerns around continued pressure in its two growth engines: the Watchman device and Farapulse.
As a result, we exited the position.
Applied Materials contributed to performance in the second quarter following strong quarterly results and significant customer announcements that reinforced the multi-year growth demand outlook from AI compute and infrastructure, particularly the memory upcycle leveraged to AI and high-bandwidth memory (HBM).
Also held
Its investment theses
- Micron TechnologyJun 2026Micron Technology benefits from a structurally stronger AI-driven memory upcycle, tight supply, rising HBM demand and improved margins from long-term supply agreements.
- Applied MaterialsJun 2026Applied Materials is positioned to benefit from multi-year AI and memory-related wafer fab equipment growth, with leading exposure to key end markets and strong customer capex plans.
- Advanced Micro DevicesJun 2026Advanced Micro Devices is a long-term AI and computing beneficiary gaining share in CPUs and accelerators, with a credible path to revenue, margin and earnings growth.
- Exxon MobilJun 2026Exxon Mobil offers resilience through its strong balance sheet, advantaged upstream assets, refining support and long-term growth options beyond the oil cycle.